CPI-637 is a selective inhibitor of BET (Bromodomain and Extra-Terminal) proteins, which play a key role in regulating gene expression, particularly in processes related to inflammation and cancer. It is primarily used in research settings to study its potential therapeutic effects in oncology, targeting specific pathways associated with cancer progression, such as in various leukemias and lymphomas, with the aim of developing novel treatments. Additionally, CPI-637 is utilized in preclinical studies to assess its impact on tumor growth and survival, providing insights into its potential as a future anticancer agent. It is also explored for reducing inflammation in chronic diseases, including arthritis and neurological disorders. Its application extends to biochemical assays and drug discovery efforts, where it helps identify new therapeutic targets and optimize drug candidates. These investigations remain experimental and require further studies to confirm efficacy and safety for clinical use.